Group 1 - The company plans to invest 420 million yuan in a bio-manufacturing base for raw materials and health dietary supplements in the Inner Mongolia region [1] - The project will involve approximately 300 million yuan in fixed asset investment, with the local government providing support and favorable policies [1] - The investment aims to leverage the geographical advantages and resource endowments of the region, enhancing production efficiency and reducing costs [1] Group 2 - The project is subject to various pre-approval processes, including environmental assessments and construction permits, which may pose challenges [2] - Potential risks include changes in national or local industrial policies, environmental standards, and market fluctuations that could affect project execution and returns [2] - The investment agreement reflects current market conditions and may face uncertainties that could impact the project's progress and expected benefits [2]
拓新药业拟4.2亿元投建内蒙古原料药及健康膳食补充剂基地